Abstract
Structure based design has been widely used in many drug development programs. In parallel with the evolution of high performance computing systems and versatile molecular modeling programs, structure based drug design has become indispensible in many research areas. CYP51 is a proven therapeutic target for anti-fungal drugs. While anti-fungal drugs targeting CYP51 have a long history and a large pool of anti-fungal CYP51 inhibitor therapeutics are now available, structure based design of therapeutic agents targeting CYP51 has only recently been attempted, Here, we present structural features of CYP51 and its complexes formed with lanosterol, azole drugs, and specifically designed inhibitors. In particular, the first x-ray co-crystal structures of fungal CYP51 complexed with lanosterol and itraconazole are compared with co-crystal structures of other protozoal CYP51 enzymes. It is anticipated that comparative analyses of these structures, and other structures that emerge in coming years, will provide clear rationales to address issues in the development of CYP51 drug candidates such as drug resistant, selectivity against other human CYP enzymes, and diversity of CYP51 inhibitors.
Keywords: Anti-fungal azole drugs, Anti-parasitic agents, Computer guided drug design, CYP51, Infectious disease, Structure based drug design.
Current Topics in Medicinal Chemistry
Title:Structure Based Design of CYP51 Inhibitors
Volume: 17 Issue: 1
Author(s): Jun Yong Choi and William R. Roush
Affiliation:
Keywords: Anti-fungal azole drugs, Anti-parasitic agents, Computer guided drug design, CYP51, Infectious disease, Structure based drug design.
Abstract: Structure based design has been widely used in many drug development programs. In parallel with the evolution of high performance computing systems and versatile molecular modeling programs, structure based drug design has become indispensible in many research areas. CYP51 is a proven therapeutic target for anti-fungal drugs. While anti-fungal drugs targeting CYP51 have a long history and a large pool of anti-fungal CYP51 inhibitor therapeutics are now available, structure based design of therapeutic agents targeting CYP51 has only recently been attempted, Here, we present structural features of CYP51 and its complexes formed with lanosterol, azole drugs, and specifically designed inhibitors. In particular, the first x-ray co-crystal structures of fungal CYP51 complexed with lanosterol and itraconazole are compared with co-crystal structures of other protozoal CYP51 enzymes. It is anticipated that comparative analyses of these structures, and other structures that emerge in coming years, will provide clear rationales to address issues in the development of CYP51 drug candidates such as drug resistant, selectivity against other human CYP enzymes, and diversity of CYP51 inhibitors.
Export Options
About this article
Cite this article as:
Choi Yong Jun and Roush R. William, Structure Based Design of CYP51 Inhibitors, Current Topics in Medicinal Chemistry 2017; 17 (1) . https://dx.doi.org/10.2174/1568026616666160719164933
DOI https://dx.doi.org/10.2174/1568026616666160719164933 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mur Ligase Inhibitors as Anti-bacterials: A Comprehensive Review
Current Pharmaceutical Design Latent Tuberculosis: Is There a Role for Thioridazine?
Recent Patents on Anti-Infective Drug Discovery Editorial [Hot Topic: N-Acetyltransferases: Lessons Learned from Eighty Years of Research (Guest Editor: Jose A.G. Agundez) ]
Current Drug Metabolism Bixin Action in the Healing Process of Rats Mouth Wounds
Current Pharmaceutical Biotechnology Preparation and Antitubercular Activities of Palindromic Hydrazinecarbothioamides and Carbonothioic Dihydrazides
Letters in Drug Design & Discovery Design, Synthesis and Docking Study of Some Novel Isatin- Quinoline Hybrids as Potential Antitubercular Agents
Anti-Infective Agents Systems Biology of Apoptosis and Survival: Implications for Drug Development
Current Pharmaceutical Design New Developments in Antimicrobial Use in Sepsis
Current Pharmaceutical Design Recent Progress in Biological Activities of Indole and Indole Alkaloids
Mini-Reviews in Medicinal Chemistry New Bioactive Metabolites from the Marine-derived Fungi Aspergillus
Mini-Reviews in Medicinal Chemistry Molecular Modeling Based Synthesis and Evaluation of <i>In vitro</i> Anticancer Activity of Indolyl Chalcones
Current Topics in Medicinal Chemistry Involvement of IL-1R/TLR Signalling in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis
Current Molecular Medicine Effect of Polarization of Ligand Charges and Estimation of MM/GBSA Binding Free Energies of Some Pyrazolo[3,4-d]pyrimidine Inhibitors of Mycobacterium Tuberculosis in View of Experimental Results
Current Enzyme Inhibition Challenges and Advances in Infection Control of Hematopoietic Stem Cell Transplant Recipients
Infectious Disorders - Drug Targets Immunomodulatory Actions of Vitamin D Metabolites and their Potential Relevance to Human Lung Disease
Current Respiratory Medicine Reviews Applications of Stripping Voltammetry at Carbon Paste and Chemically Modified Carbon Paste Electrodes to Pharmaceutical Analysis
Current Pharmaceutical Analysis Innate Immunity and Primary Biliary Cirrhosis
Current Molecular Medicine Meet the Editorial Board Member
Current Pharmaceutical Biotechnology Synthesis and Anti-onchocercal Activity of Isonicotinoylhydrazones and their Copper(II) and Zinc(II) Complexes
Anti-Infective Agents Tumor Markers in Patients with Benign and Malignant Pulmonary Diseases; Competitive Evaluation of ProGRP, NSE and Cyfra 21-1
Recent Patents on Biomarkers